Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

AcnePsoriasis

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

J Eur Acad Dermatol Venereol

Motedayen Aval L, Yiu ZZN, Alabas OA, Griffiths CEM, Reynolds NJ, Hampton PJ, Smith CH, Warren RB, BADBIR Study Group

doi: 10.1111/jdv.20739

Osteoarthritis

Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: a target trial emulation study

Ann Rheum Dis

Hatano M, Sasabuchi Y, Okada A, Kimura Y, Ishikura H, Tanaka T, Saito T, Tanaka S, Yasunaga H

doi: 10.1016/j.ard.2025.06.2124

Gout

Comparative Cardiovascular Safety of NSAID versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients with Gout: Target Trial Emulations

Arthritis Rheumatol

Yokose C, McCormick N, Lu N, Jiang B, Tan K, Chigurupati S, Rai S, Challener G, Aviña-Zubieta JA, Cipolletta E, Abhishek A, Gaffo A, Januzzi JL, Zhang Y, Choi HK

doi: 10.1002/art.43259

Psoriasis

Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study

J Eur Acad Dermatol Venereol

Miao Y, Beauchet A, Piram M, McPherson T, Torres T, Yesli Y, Aubert H, Bodemer C, Bertoli C, Tardieu M, Hubiche T, Bonniaud B, Neri I, Chessa MA, Lasek A, Prignano F, Barbarot S, Bursztejn AC, Leducq S, Sergeant M, Puzenat E, Chiaverini C, Sigg N, Mallet S, Miquel J, Pourchot D, Patel KX, Burden-Teh E, Flohr C, Di Lernia V, Mahé E, GrPso of the Société Française de Dermatologie; Groupe de Recherche de la Société Française de Dermatologie Pédiatrique

doi: 10.1111/jdv.70108

Rheumatoid Arthritis

Prospective study on mental status in rheumatoid arthritis patients on tumour necrosis factor vs non- tumour necrosis factor-targeted therapies after achieving treatment target

Rheumatology (Oxford)

Fujii T, Murata K, Nakabo S, Onishi A, Murakami K, Tanaka M, Morinobu A, Matsuda S

doi: 10.1093/rheumatology/keaf598

Psoriasis

Residual Inflammation in Patients with Psoriasis Treated with Biologic Therapy: Findings from 3 Prospective Observational Cohorts

J Invest Dermatol

Lecumberri A, Berna-Rico E, Gelfand JM, Svedbom A, Abbad-Jaime de Aragón C, Neria F, Monge D, Ballester-Martínez A, Pindado-Ortega C, Castellanos-González M, Llamas-Velasco M, Barderas MG, Solís J, Fernández-Friera L, Jaén P, Stahle M, Mehta NN, González-Cantero Á

doi: 10.1016/j.jid.2025.03.014

Atopic Dermatitis

Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa

J Eur Acad Dermatol Venereol

Nikolakis G, Alpsoy E, Anzengruber F, Augustin M, Bechara FG, Becherel PA, Benhadou F, Bettoli V, Cabete J, Caposiena Caro RD, Di Cesare A, Damiani G, Dini V, Giamarellos-Bourboulis EJ, Gáspár K, Glasenhardt K, Guillem P, Hafner A, Horvath B, Ingram JR, Jarienè V, Jemec GBE, Katoulis A, Kirsten N, Kokolakis G, Krajewski PK, Liakou AI, Manzo Margiotta F, Marzano AV, Martorell A, Matusiak L, Mintoff D, Molina Leyva A, Pinter A, Pirogova A, Podda M, Prignano F, Romani J, Romanelli M, Rosi E, Sahin S, Saunte DML, Schneider-Burrus S, Suppa M, Szepietowski J, Szegedi A, Thomsen SF, Tzellos T, Trigoni A, Van Der Zee HH, Van Straalen K, Valiukevičiene S, Vilarrasa E, von Stebut E, Zouboulis CC

doi: 10.1111/jdv.70264

ImmunotherapyFurther Publications Dermatology

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Lancet

Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Peña AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M, CheckMate 9DW investigators

doi: 10.1016/S0140-6736(25)00403-9

Juvenile Idiopathic Arthritis

Effect of time to start of biologic therapy on treatment response in childhood arthritis: Results from the UCAN CAN-DU study

Arthritis Rheumatol

de Jonge JB, de Roock S, Schonenberg-Meinema D, van den Berg JM, Marshall DA, Vastert SJ, Yeung RSM, Swart JF, Benseler SM, UCAN CAN‐DU and UCAN CURE consortia

doi: 10.1002/art.43401

Related content

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: a target trial emulation study

Comparative Cardiovascular Safety of NSAID versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients with Gout: Target Trial Emulations

Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study

Prospective study on mental status in rheumatoid arthritis patients on tumour necrosis factor vs non- tumour necrosis factor-targeted therapies after achieving treatment target

Residual Inflammation in Patients with Psoriasis Treated with Biologic Therapy: Findings from 3 Prospective Observational Cohorts

Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Effect of time to start of biologic therapy on treatment response in childhood arthritis: Results from the UCAN CAN-DU study